- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06343727
A High Protein Egg White Pudding for People With Kidney Failure (HiPE KF)
March 26, 2024 updated by: Seven Oaks Hospital Chronic Disease Innovation Centre
The goal of this clinical trial is to compare protein supplements in patients with kidney failure on dialysis. The main questions it aims to answer are:
- To determine whether the supplementation of egg white protein pudding in a population of individuals with kidney failure on dialysis is feasible.
- To determine whether egg white protein pudding supplementation improves serum albumin similar to other standard nutritional supplements.
- To determine the effects of the egg white protein pudding on frailty measures, dietary intakes and analytes in the blood and urine. Participants will receive either the egg white pudding (experimental) or control (Ensure plus) at the end of their dialysis treatments 3-days per week for 12 weeks.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
54
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Navdeep Tangri, MD, PhD
- Phone Number: 2046313834
- Email: ntangri@sogh.mb.ca
Study Contact Backup
- Name: Dianna Dandeneau, MSc
- Phone Number: 2046313834
- Email: ddandeneau@sogh.mb.ca
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Participant is willing and able to give informed consent for participation in the trial
- Male or female aged ≥18 years with CKD
- On chronic in-center hemodialysis for > 3 months
- Serum albumin <35 g/L
- No expected change in dialysis modality or relocation outside of Winnipeg during the intervention period (12 weeks)
Exclusion Criteria:
- Allergy to eggs
- History of renal transplant
- Serum albumin ≥ 35 g/L
- Bowel diseases
- Cancer
- Pregnancy
- Receiving chemotherapy treatment
- Inability to consume treatment product
- Allergy to study treatment ingredients
- Planning on starting an exercise program during the duration of the trial
- Inability to obtain written informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Egg white protein pudding
Participants will receive egg white pudding at the end of their dialysis treatments 3-days per week.
|
Will consume one egg white protein pudding at the end of their dialysis treatments 3-days per week for 12 weeks
Will consume one Ensure Plus at the end of their dialysis treatments 3-days per week for 12 weeks
|
Active Comparator: : Standard dietary supplement
Participants will receive Ensure Plus at the end of their dialysis treatments 3-days per week.
|
Will consume one egg white protein pudding at the end of their dialysis treatments 3-days per week for 12 weeks
Will consume one Ensure Plus at the end of their dialysis treatments 3-days per week for 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Weekly recruitment rate
Time Frame: 12 months
|
Number of new participants per weeks of active recruitment
|
12 months
|
Eligibility to randomization ratio
Time Frame: Measured at the end of 12 weeks.
|
A ratio of eligibility to randomization expressed as percentage will be collected at 12 months to investigate egg pudding intervention feasibility.
|
Measured at the end of 12 weeks.
|
Adherence to Egg pudding
Time Frame: Measured at the end of12 weeks
|
Adherence to egg white product intervention calculated by consumption of >75% dispensed egg white protein products.
|
Measured at the end of12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum albumin
Time Frame: Measured at the end of 12 weeks.
|
Serum albumin is measured in grams per deciliter (g/dL)
|
Measured at the end of 12 weeks.
|
Hand grip strength
Time Frame: Measured at the end of 12 weeks.
|
Measuring the amount of static force that the hand can squeeze around a dynamometer.
Measured in kilograms and pounds.
|
Measured at the end of 12 weeks.
|
Change in gait speed
Time Frame: Measured at the end of 12 weeks.
|
Gait speed is measured by the predetermined distance/time to walk that distance (e.g., 5m/__sec)
|
Measured at the end of 12 weeks.
|
Five rep chair stand time
Time Frame: Measured at the end of 12 weeks.
|
the amount of time it takes for a participant to get up out of a chair five times measured in seconds
|
Measured at the end of 12 weeks.
|
Tandem balance time
Time Frame: Measured at the end of 12 weeks.
|
Measured in Seconds
|
Measured at the end of 12 weeks.
|
Serum bicarbonate
Time Frame: Measured at the end of 12 weeks.
|
Serum bicarbonate concentration in milliequivalents per liter (mEq/L)
|
Measured at the end of 12 weeks.
|
Calcium
Time Frame: Measured at the end of 12 weeks.
|
Total blood calcium concentration in mmol/L
|
Measured at the end of 12 weeks.
|
Urine albumin
Time Frame: Measured at the end of 12 weeks.
|
Total urine albumin concentration in µg/min
|
Measured at the end of 12 weeks.
|
chloride
Time Frame: Measured at the end of 12 weeks.
|
Total blood chloride concentration in mmol/L
|
Measured at the end of 12 weeks.
|
phosphorus
Time Frame: Measured at the end of 12 weeks.
|
The total blood phosphorus concentration in mmol/L
|
Measured at the end of 12 weeks.
|
Potassium
Time Frame: Measured at the end of 12 weeks.
|
The total blood potassium concentration in mmol/L
|
Measured at the end of 12 weeks.
|
Sodium
Time Frame: Measured at the end of 12 weeks.
|
The total sodium concentration in mmol/L
|
Measured at the end of 12 weeks.
|
HbA1c
Time Frame: Measured at the end of 12 weeks.
|
Total blood glucose concentration in mmol/L
|
Measured at the end of 12 weeks.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
May 1, 2024
Primary Completion (Estimated)
May 1, 2025
Study Completion (Estimated)
July 1, 2025
Study Registration Dates
First Submitted
February 7, 2024
First Submitted That Met QC Criteria
March 26, 2024
First Posted (Actual)
April 3, 2024
Study Record Updates
Last Update Posted (Actual)
April 3, 2024
Last Update Submitted That Met QC Criteria
March 26, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HS25870 (H2023:026)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Frailty
-
University of PennsylvaniaCompleted
-
Instituto Tecnologico y de Estudios Superiores...Not yet recruiting
-
Longeveron Inc.CompletedAging FrailtyUnited States
-
Longeveron Inc.CompletedAging FrailtyUnited States
-
The Hong Kong Polytechnic UniversityCompleted
-
Xijing HospitalUnknownFrailty SyndromeChina
-
Region ZealandUniversity of Southern DenmarkActive, not recruitingFrailty SyndromeDenmark
-
IRCCS Centro San Giovanni di Dio FatebenefratelliCompleted
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
University of ValenciaCompletedFrailty SyndromeSpain
Clinical Trials on Egg white protein pudding
-
University of North Carolina, Chapel HillUniversity of ArkansasCompletedFood HypersensitivityUnited States
-
The University of Texas at San AntonioTexas State University; American Egg BoardCompleted
-
Newtricious R&D BVMaastricht UniversityCompleted
-
Newtricious R&D BVCompleted
-
Hugh A Sampson, MDNational Institute of Allergy and Infectious Diseases (NIAID); Consortium of...CompletedFood AllergyUnited States
-
Fairfield UniversityUnited States Department of Agriculture (USDA)Completed
-
Federico II UniversityUnknownRenal Insufficiency, Chronic | Hyperphosphatemia | DialysisItaly
-
Aristotle University Of ThessalonikiEuropean Commission; Greek Ministry of DevelopmentCompletedExercise Training | Dietary SupplementsGreece
-
Purdue UniversityCompleted